ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-22

Study Completion Date

2009-09-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

NCT03808610

Recurrent B Acute Lymphoblastic Leukemia Recurrent T Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia +1 more

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

NCT03752138

Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

WITHDRAWN PHASE1

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

NCT00343369

Leukemia

UNKNOWN NA

Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

NCT00764907

Leukemia

UNKNOWN PHASE3

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00075725

Acute Lymphoblastic Leukemia Adult B Acute Lymphoblastic Leukemia Childhood B Acute Lymphoblastic Leukemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients will receive the 2 courses of chemotherapy unless medical complications prevent the administration of some of the drugs. Treatment for the first 2 courses of therapy will last about 2 months.

Treatment on this study will consist of a combination of 8 anti-cancer medications. The 8 anticancer medicines are ABT-751, dexamethasone, PEG-asparaginase, doxorubicin, cytarabine (Ara-C), methotrexate (MTX), cyclophosphamide, and 6-thioguanine. All the drugs except ABT-751 are well known anti-cancer drugs and have been used extensively in the treatment of cancer.

During the Phase I portion of this study, when you enroll, you will be given an assigned dose of ABT-751. The dose of ABT-751 will be based on doses given in previous studies done with adults and children. At each dose level of ABT-751, between 3 and 6 children will receive ABT-751 in combination with chemotherapy. If the side effects are not too severe, the next group of children will receive a higher dose. The dose will continue to be increased until we find the dose that causes serious side effects. Your dose of ABT-751 will not be increased. If you have bad side effects, your dose may be decreased.

The dose used during the Phase 2 part of this study will be determined by the outcome of the Phase I study. The highest dose used in Phase I that was tolerated without serious side effects will be the one used in Phase 2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Pediatric ALL Relapsed Pediatric ALL Acute Lymphoblastic Leukemia Refractory Pediatric ALL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Level 1

Treatment Dose of ABT-751 is 80 mg/m2/day

Tx Course 1:

• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate

Tx Course 2:

• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751

Tx Courses 3-12 (maintenance courses):

• ABT-751, IT Methotrexate

Group Type EXPERIMENTAL

ABT-751

Intervention Type DRUG

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Dexamethasone

Intervention Type DRUG

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

PEG-asparaginase

Intervention Type DRUG

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Doxorubicin

Intervention Type DRUG

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Cytarabine

Intervention Type DRUG

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Methotrexate

Intervention Type DRUG

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Cyclophosphamide

Intervention Type DRUG

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

6-thioguanine

Intervention Type DRUG

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Dose Level 2

Treatment Dose of ABT-751 is 100 mg/m2/day

Tx Course 1:

• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate

Tx Course 2:

• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751

Tx Courses 3-12 (maintenance courses):

• ABT-751, IT Methotrexate

Group Type EXPERIMENTAL

ABT-751

Intervention Type DRUG

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Dexamethasone

Intervention Type DRUG

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

PEG-asparaginase

Intervention Type DRUG

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Doxorubicin

Intervention Type DRUG

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Cytarabine

Intervention Type DRUG

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Methotrexate

Intervention Type DRUG

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Cyclophosphamide

Intervention Type DRUG

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

6-thioguanine

Intervention Type DRUG

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Dose Level 3

Treatment Dose of ABT-751 is 125 mg/m2/day

Tx Course 1:

• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate

Tx Course 2:

• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751

Tx Courses 3-12 (maintenance courses):

• ABT-751, IT Methotrexate

Group Type EXPERIMENTAL

ABT-751

Intervention Type DRUG

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Dexamethasone

Intervention Type DRUG

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

PEG-asparaginase

Intervention Type DRUG

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Doxorubicin

Intervention Type DRUG

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Cytarabine

Intervention Type DRUG

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Methotrexate

Intervention Type DRUG

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Cyclophosphamide

Intervention Type DRUG

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

6-thioguanine

Intervention Type DRUG

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Dose Level 4

Treatment Dose of ABT-751 is 150 mg/m2/day

Tx Course 1:

• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate

Tx Course 2:

• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751

Tx Courses 3-12 (maintenance courses):

• ABT-751, IT Methotrexate

Group Type EXPERIMENTAL

ABT-751

Intervention Type DRUG

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Dexamethasone

Intervention Type DRUG

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

PEG-asparaginase

Intervention Type DRUG

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Doxorubicin

Intervention Type DRUG

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Cytarabine

Intervention Type DRUG

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Methotrexate

Intervention Type DRUG

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Cyclophosphamide

Intervention Type DRUG

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

6-thioguanine

Intervention Type DRUG

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Dose Level 5

Treatment Dose of ABT-751 is 175 mg/m2/day

Tx Course 1:

• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate

Tx Course 2:

• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751

Tx Courses 3-12 (maintenance courses):

• ABT-751, IT Methotrexate

Group Type EXPERIMENTAL

ABT-751

Intervention Type DRUG

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Dexamethasone

Intervention Type DRUG

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

PEG-asparaginase

Intervention Type DRUG

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Doxorubicin

Intervention Type DRUG

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Cytarabine

Intervention Type DRUG

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Methotrexate

Intervention Type DRUG

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Cyclophosphamide

Intervention Type DRUG

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

6-thioguanine

Intervention Type DRUG

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Dose Level 0

Treatment Dose of ABT-751 is 65 mg/m2/day

Tx Course 1:

• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate

Tx Course 2:

• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751

Tx Courses 3-12 (maintenance courses):

• ABT-751, IT Methotrexate

Group Type EXPERIMENTAL

ABT-751

Intervention Type DRUG

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Dexamethasone

Intervention Type DRUG

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

PEG-asparaginase

Intervention Type DRUG

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Doxorubicin

Intervention Type DRUG

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Cytarabine

Intervention Type DRUG

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Methotrexate

Intervention Type DRUG

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Cyclophosphamide

Intervention Type DRUG

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

6-thioguanine

Intervention Type DRUG

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Dose Level -1

Treatment Dose of ABT-751 is 50 mg/m2/day

Tx Course 1:

• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate

Tx Course 2:

• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751

Tx Courses 3-12 (maintenance courses):

• ABT-751, IT Methotrexate

Group Type EXPERIMENTAL

ABT-751

Intervention Type DRUG

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Dexamethasone

Intervention Type DRUG

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

PEG-asparaginase

Intervention Type DRUG

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Doxorubicin

Intervention Type DRUG

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Cytarabine

Intervention Type DRUG

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Methotrexate

Intervention Type DRUG

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Cyclophosphamide

Intervention Type DRUG

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

6-thioguanine

Intervention Type DRUG

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABT-751

Treatment Course 1:

Oral capsule to be given daily for 21 days at assigned dose.

Treatment Course 2:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.

Treatment Course 3:

ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest.

Intervention Type DRUG

Dexamethasone

In Treatment Course 1 only:

* 10 mg/m2/day divided BID.
* Take dexamethasone by mouth days 1-14.

Intervention Type DRUG

PEG-asparaginase

In Treatment Course 1:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on days 4, 11 and 18.

In Treatment Course 2:

* 2500 IU's/m2/day.
* Intramuscular injection (IM) on day 15.

Intervention Type DRUG

Doxorubicin

In Treatment Course 1 only:

• 60 mg/m2/day IV over 15 minutes on day 1.

Intervention Type DRUG

Cytarabine

* Given Intrathecally on day 1 of course 1 at the dose defined by age below.

* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients \>3 years of age
* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.

In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12.

Intervention Type DRUG

Methotrexate

In Treatment Course 1:

• Given Intrathecally on day 15 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 2:

• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.

* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients \>9 years of age

In Treatment Course 3:

Intrathecally on day 1 at the age-defined dose

Intervention Type DRUG

Cyclophosphamide

Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.

Intervention Type DRUG

6-thioguanine

Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Antineoplastics Decadron Dexasone Diodex Hexadrol Maxidex Elspar Kidrolase L-asparaginase Erwinia L-asparaginase Adriamycin Rubex Cytosar-U Ara-C Arabinosylcytosine Otrexup Rasuvo Rheumatrex Trexall Amethopterin Methotrexate Sodium MTX Cytoxan Neosar Thioguanine Tabloid 6-TG 2-Amino-6-Mercaptopurine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age Patients must be \< 21 years of age when enrolled onto this study. T2005-001 Protocol version 6/27/2007 17
2. Diagnosis

Patients must have relapsed or refractory ALL with a M3 marrow (marrow blasts \>25%) without clinical evidence of testicular disease or laboratory evidence of CNS disease defined as CSF WBC \> 5 cells/microliter and blasts. (See Appendix I for method of evaluating traumatic lumbar punctures.) Patients in early first relapse (defined as a patient who relapses less than 36 months from their initial remission \[CR1\]) are eligible for the phase I portion of the trial.
3. Performance Level Karnofsky \> 60% for patients \> 10 years of age and Lansky \> 60% for patients \< 10 years of age.
4. Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

1. Prior anthracycline exposure: Patients must have less than 300mg/m2 lifetime exposure of anthracycline chemotherapy. (See Appendix III for calculation criteria)
2. Stem Cell Transplant (SCT): Patients are eligible 6 months after allogeneic stem cell transplant as long as patients are not actively being treated for graft-versus-host-disease (GvHD).
3. During the phase I portion of the trial, there is no limit on the number of prior treatment regimens.
4. During the phase II portion of the trial, patients must have had two or more prior therapeutic attempts defined as:

* Persistent initial disease after two induction attempts, or
* Relapse after one-reinduction attempt (2nd relapse), or
* Persistent disease after first relapse and initial re-induction attempt (Patients in any first relapse are not eligible for the phase II portion of the study)
5. During the phase II portion of the trial, patients must have no more than 3 prior therapeutic attempts and it must be at least 6 months since the last treatment with a "VPLD" induction/re-induction regimen.
5. Reproductive Function

1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment and within 48 hours of starting therapy.
2. Female patients with infants must agree not to breastfeed their infants while on this study.
3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for 3 months following completion of therapy.

Exclusion Criteria

1. Drug Allergies

Patients will be excluded if they have allergies to the following drugs:
* Asparaginase products
* Sulfa containing medications
2. Renal Function Patients will be excluded if their serum creatinine is \> the upper limit of normal (ULN) for age at the institution's laboratory.
3. Liver/Pancreatic Function

1. Direct bilirubin \> 1.5x the institutional ULN for age. A total bilirubin result that is less than 1.5 times the institutional ULN for age may be used for eligibility if a direct bilirubin result is not available.
2. SGPT (ALT) \> 4 x institutional ULN
3. Grade 3 or greater pancreatitis as defined by the CTCAE v3.0
4. Amylase or Lipase \> 2 x institutional ULN
4. Cardiac Function Patients will be excluded if their shortening fraction by echocardiogram is less than 30%.
5. Infection Patients will be excluded if they have an active, uncontrolled infection.

1. Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0 criteria.
2. Patients with grade 2 or greater Ileus (neuroconstipation) per CTC 3.0 criteria.
3. Patients currently being treated with coumadin.
4. Patients currently being treated with colchicines.
5. Patients planning on receiving other investigational agents while on this study. (An investigational agent is defined as any drug not currently approved for use in humans.)
6. Patients planning on receiving other anti-cancer therapies while on this study.
7. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
8. Patients who, based on BSA and current dose level, require a daily dose of ABT-751 that is less than 25mg per day.
9. Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT Ara-C or IT MTX were given within 48 hours of study enrollment as part of the diagnostic lumbar procedure. These patients will not participate in the CSF PK portion of the study.

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No